Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
03 sept. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024
26 août 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 07h10 HE
|
Unicycive Therapeutics, Inc.
– On Track to Submit OLC New Drug Application (NDA) by End of August 2024 – LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company”...
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
17 juil. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
11 juil. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)
10 juil. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE...
Unicycive Therapeutics Joins Russell Microcap® Index
01 juil. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
25 juin 2024 07h30 HE
|
Unicycive Therapeutics, Inc.
– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS...
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress
28 mai 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate...
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference
23 mai 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...